Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Seres Therapeutics ( (MCRB) ) has issued an announcement.
Seres Therapeutics reported its fourth-quarter and full-year 2025 financial results on March 12, 2026, alongside updates on its refocused pipeline in inflammatory and immune diseases. The company posted a modest net income of $5.7 million from continuing operations in 2025, reversing a $125.8 million loss in 2024, driven by lower operating expenses, installment gains from the VOWST sale to Nestlé, and payments for transition services.
Seres highlighted progress on SER-155 and SER-603, including a fully enrolled investigator-sponsored SER-155 study in immune checkpoint inhibitor–related enterocolitis with data expected in the second quarter of 2026. The company is advancing Phase 2–ready SER-155 for preventing serious bloodstream infections in allo-HSCT patients and preparing IND-enabling work for SER-603 in inflammatory bowel disease, while actively seeking partnerships and funding to support these programs.
Cost-cutting efforts sharply reduced research and development and general and administrative expenses in 2025, reflecting a leaner operating model after divesting the VOWST business, now classified as discontinued operations. As of December 31, 2025, Seres held $45.8 million in cash and cash equivalents, including proceeds from an at-the-market equity program, and projects its current cash position will fund operations through the third quarter of 2026, underscoring the urgency of securing additional capital or strategic collaborations.
The most recent analyst rating on (MCRB) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Seres Therapeutics stock, see the MCRB Stock Forecast page.
Spark’s Take on MCRB Stock
According to Spark, TipRanks’ AI Analyst, MCRB is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue base, ongoing operating losses, and sizable cash burn) and a soft technical setup (below key moving averages with negative MACD). Offsetting this, the latest earnings call was constructive on clinical progress and near-term catalysts, but the investment case remains meaningfully funding-dependent, with a limited stated cash runway.
To see Spark’s full report on MCRB stock, click here.
More about Seres Therapeutics
Seres Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel live biotherapeutics for inflammatory and immune diseases. The company previously led the development and FDA approval of VOWST, the first orally administered microbiome therapeutic, which it later divested to Nestlé Health Science, and is now advancing pipeline candidates such as SER-155 and SER-603 targeting serious complications in cancer and inflammatory bowel disease.
Average Trading Volume: 71,438
Technical Sentiment Signal: Sell
Current Market Cap: $80.79M
For a thorough assessment of MCRB stock, go to TipRanks’ Stock Analysis page.